Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study
Open Access
- 25 January 2021
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
- Vol. 38 (1), 15-21
- https://doi.org/10.4274/tjh.galenos.2021.2020.0695
Abstract
Objective: The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to be associated with poor outcomes. In this study, we assessed the prognostic values of antithrombin (AT) activity levels and the impact of fresh frozen plasma (FFP) treatment on outcome. Materials and Methods: Conventional coagulation parameters as well as AT activity levels and outcomes of 104 consecutive critically ill acute respiratory distress syndrome (ARDS) patients with laboratory-confirmed COVID-19 disease were retrospectively analyzed. Patients with AT activity below 75% were treated with FFP. Maximum AT activity levels achieved in those patients were recorded. Results: AT activity levels at admission were significantly lower in nonsurvivors than survivors (73% vs. 81%). The cutoff level for admission AT activity was 79% and 58% was the lowest AT for survival. The outcome in those patients who had AT activity levels above 75% after FFP treatment was better than that of the nonresponding group. As well as AT, admission values of D-dimer, C-reactive protein, and procalcitonin were coagulation and inflammatory parameters among the mortality risk factors. Conclusion: AT activity could be used as a prognostic marker for survival and organ failure in COVID-19-associated ARDS patients. AT supplementation therapy with FFP in patients with COVID-19-induced hypercoagulopathy may improve thrombosis prophylaxis and thus have an impact on survival.Keywords
This publication has 24 references indexed in Scilit:
- Antithrombin: anti-inflammatory properties and clinical applicationsThrombosis and Haemostasis, 2016
- Antithrombin and mortality in severe pneumonia patients with sepsis‐associated disseminated intravascular coagulation: an observational nationwide studyJournal of Thrombosis and Haemostasis, 2014
- Acute Respiratory Distress SyndromeJAMA, 2012
- Expert consensus for the treatment of disseminated intravascular coagulation in JapanThrombosis Research, 2010
- Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsisCritical Care, 2005
- Heparin resistance.2003
- Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cellsBlood, 2002
- The serine protease inhibitor antithrombin III inhibits LPS‐mediated NF‐κB activation by TLR‐4FEBS Letters, 2001
- Fresh Frozen Plasma: A Solution to Heparin Resistance during Cardiopulmonary BypassThe Annals of Thoracic Surgery, 1984
- Antithrombin III in Fresh Frozen Plasma, Cryoprecipitate, and Cryoprecipitate‐depleted PlasmaTransfusion, 1979